CXCR2 and breast carcinoma: Taken together, our findings elucidate a novel mechanism of IL8 signaling and identify Shp1 as a promising therapeutic target, highlighting the potential of modulating the CXCR2-Shp1 axis to limit invasiveness and metastasis in aggressive breast cancer subtypes, particularly TNBC.